Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Liabilities and Shareholders Equity: 2020-2024

Historic Liabilities and Shareholders Equity for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to $284.0 million.

  • Foghorn Therapeutics' Liabilities and Shareholders Equity fell 33.53% to $205.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $973.9 million, marking a year-over-year decrease of 17.32%. This contributed to the annual value of $284.0 million for FY2024, which is 0.68% down from last year.
  • Per Foghorn Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $284.0 million for FY2024, which was down 0.68% from $285.9 million recorded in FY2023.
  • Foghorn Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $519.8 million for FY2021, and its period low was $255.6 million during FY2020.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $285.9 million (2023), whereas its average is $324.9 million.
  • In the last 5 years, Foghorn Therapeutics' Liabilities and Shareholders Equity skyrocketed by 103.36% in 2021 and then decreased by 29.38% in 2023.
  • Yearly analysis of 5 years shows Foghorn Therapeutics' Liabilities and Shareholders Equity stood at $255.6 million in 2020, then skyrocketed by 103.36% to $519.8 million in 2021, then decreased by 22.10% to $404.9 million in 2022, then declined by 29.38% to $285.9 million in 2023, then declined by 0.68% to $284.0 million in 2024.